Moody’s rates Abbott Labs notes A2

Moody's Investors Service said it assigned an A2 rating to Abbott Laboratories' new senior unsecured note offering and a provisional A2 to its senior unsecured shelf registration.

There is no change to Abbott's existing A2 long-term or Prime-1 short-term ratings.

The outlook is stable.

Moody’s said the A2 rating reflects Abbott's position as one of the largest and well-diversified medical products companies. The company will maintain good market positioning in its product segments, including its remaining emerging markets branded generics business, the agency said.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.